

DAFTAR PUSTAKA

- Ackerman, B.H., Guilday, R.E., Reigart, C.L., Patton, M.L. & Haith, L.R. 2013. Evaluation of the relationship between elevated vancomycin trough concentrations and increased efficacy and/or toxicity. *J. Burn. Care. Res.* 34: 1-9.
- Akil, I.O., Mir, S. 2001. Hemodiafiltration for vancomycin overdose in a patient with end-stage renal failure. *Pediatr. Nephrol.* 16: 1019-1021.
- An, S.Y., Hwang, E.K., Kim, J.H., Kim, J.E., Jin, H.J., Jin, S.M., Kyun, J.O., Lee, Y.H., Park, H.S., Choi, Y.W., Lim, S.K. & Ye, Y.M. 2011. Vancomycin-associated spontaneous cutaneous adverse drug reactions. *Allergy Asthma Immunol. Res.* 3(3): 194-198.
- Ashley, C. & Currie, A. 2009. *The Renal Drug Handbook*, 3th Edition, New York: Radcliffe Publishing Oxford
- Balen, R.M., Betts, T. & Ensom, M.H.H. 2000. Vancomycin overdose in a 6-month-old girl. *CHJP.* 53(1): 32-35.
- Bauer, L.A. 2006. *Clinical Pharmacokinetics Handbook*. New York: McGraw-Hill Companies.
- Bauer, L.A. 2008. *Applied Clinical Pharmacokinetics*. 2nd Ed. New York: The Graw-Hill Companies.
- Baxter, K. 2010. *Stockley's Drug Interactions A Source Book of Interactions Their Mechanism Clinical Importance and Management Drug Interactions. Ninth Edition*, London: Pharmaceutical Press.
- Bayer, A.S. & Murray, B.E. 2009. Initial low-dose aminoglycosides in *Staphylococcus aureus* bacteremia: good science, urban legend, or just plain toxic? *Clin. Infect. Dis.* 48: 713-721.
- Bosso, J.A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P.B., Swindler, J. & Mauldin, P.D. 2011. Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial. *Antimicrob. Agents Chemother.* 55: 5475-5479.
- Brown, D.L., Lalla, C.D. and Masselink, A.J. 2013. AUC versus Peak-Trough Dosing of Vancomycin: Applying New Pharmacokinetic Paradigms to an Old Drug. *Ther. Drug. Monit.* 35: 443-449.
- Butranova, O.I. & Razdrogina, T.N. 2015. Antibiotics for skin and soft tissues infections in type 2 diabetes mellitus. *Int. J. Risk. Saf. Med. Suppl* 1:S57-S58.

- Callum, L.M. 2014. Optimal Medication Dosing in Patients with Diabetes Mellitus and Chronic Kidney Disease, *Can. J. Diabetes*. 38(5): 334-343.
- Cecilia, C. & Maramba-Lazarte, M.D. 2010. Determining correct dosing regimens of antibiotics based on the their bactericidal activity. *PIDSP Journal*. 11(2): 44-49
- Craig, C.R., & Stitzel, R.E. 2007. *Modern Pharmacology with Clinical Application*. New York: The McGraw-Hill Companies.
- Crew, P., Heintz, S.J. & Heintz, B.H. 2015. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis. *Am. J. Health-Syst Pharm*. 72(1): 1856-1864.
- Departemen Kesehatan Republik Indonesia. 1995. *Farmakope Indonesia Edisi IV*. Jakarta: Direktorat Jenderal Pengawasan Obat dan Makanan.
- Departemen Kesehatan. 2011. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/Menkes/Per/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Departemen Kesehatan Republik Indonesia. 2015. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 02.02/Menkes/523/2015 tentang Formularium Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Doogue, M.P. & Polasek, T.M. 2011. Drug Dosing in Renal Disease. *Clin. Biochem. Rev*. 32(2): 69-73.
- Elyasi, S., Khalili, H., Dashti-Khavidaki, S. & Mohammadpour, A. 2012. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factor and special populations. A literature review. *Eur.J. Clin. Pharmacol*. 68(9): 1243-1255.
- Escobar, L., Andresen, M., Downey, P., Gai, M.N., Regueira, T., Borquez, T., Lipman, J. & Roberts, J.A. 2014. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. *Int. J. Antimicrob. Agents*. 44(2): 163-167.
- Giusti, D.L. & Hayton, W.L. 1973. Dosage regimen adjustment in renal impairment. *Drug Intell. Clin. Pharm*. 7: 382-387.
- Goodman & Gilman. 2006. *The Pharmacological Basis of Therapeutics*. 11th Ed. New York: The Mc. Graw-Hill Companies.
- Goodman & Gilman. 2007. *Dasar Farmakologi Terapi*. Edisi 10. Jakarta: EGC.
- Gray, A., Wright, J., Goodey, V. & Bruce, L., 2011. *Injectable Dugs Guide*. London: Pharmaceutical Press.

- Green, B.N., Johnson, C.D., Egan, J.T., Rosenthal, M., Griffith, E.A., Evans, M.W. 2012. Methicillin-resistant *Staphylococcus aureus*: an overview for manual therapists. *J. Chiropr. Med.* 11(1): 64-76.
- Gritter, R.J., Bobbit, J.M., & Schwarting, A.E. 1991. *Pengantar Kromatografi*. (Edisi kedua). Penerjemah: Kosasih Padmawinata. Bandung: Penerbit ITB.
- Gunawan, G.S. 2009. *Farmakologi dan Terapan*. Edisi 5. Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia.
- Gupta, A., Biyani, M. & Khaira, A. 2011. Vancomycin nephrotoxicity: myths and facts. *Neth. J. Med.*, 69(9):379-383.
- Hanrahan, T., Whitehouse T., Lipman, J. & Roberts, J.A. 2015. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. *Int. J. Antimicrob. Agents.* 46(3): 249-253.
- Hashizume, H., Takahashi, Y., Harada, S. & Nomoto, A. 2015. Natural lipopeptide antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of beta-lactams against methicillin-resistant *Staphylococcus aureus*. *J. Antibiot.* 68: 373-378.
- Hassan, Y., Al-Ramahi, R.J., Aziz, N.A. & Ghazali, R. 2009. Impact of a Renal Drug Dosing Service on Dose Adjustment in Hospitalized Patients with Chronic Kidney Disease. *Ann. Pharmacother.* 43: 1598-1605.
- Hazlewood, K.A., Brouse, S.D., Pitcher, W.D. & Hall, R.G. 2010. Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination? *Am. J. Med.* 123(2): 1-11.
- Hernandez, A.L., & Johnson, C.E. 1982. Estimation of creatinine clearance in children: comparison of six methods. *Clin Pharm.* 1(2): 158-161.
- Hong, L.T., Goolsby, T.A., Sherman, D.S., Mueller, S.W., Reynolds, P., Cava, L., Neumann, R. & Kiser, T.H. 2015. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. *J.Crit. Care.* 30, 1-6.
- Humbert, G., Spyker, D.A., Fillastre, J.P. & Leroy, A. 1979. Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function. *Antimicrob. Agents Chemother.* 15(1): 28-33.
- Humphreys, H., Fitzpatrick, F. & Harvey, B.J. 2015. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant *Staphylococcus aureus*: are they real, do they matter and why? *Clin. Infect. Dis.* 61(11): 1708-1714.
- Ippolito, G., Leone, S., Lauria, F.N., Nicastrì, E. & Wenzel, R.P. 2010. Methicillin-resistant *Staphylococcus aureus*: the superbug. *Int. J. Infect. Dis.* 14(Suppl 4): 7-11.

- Janknegt, R. 1990. Pharmacokinetics of antimicrobial agents in organ function impairment. *Int. J. Clin Pharm.* 12(4): 121-127.
- Karsono, B. 2006. *Ilmu Penyakit Dalam*, volume II. Jakarta: Pusat Penerbitan Departemen IPD FKUI.
- Katzung, B.G. 2012. *Basic & Clinical Pharmacology*. 12th Ed. New York: The McGraw-Hill Companies.
- Khudaibergenova, M.S. 2015. Antimicrobial use at a multi-disciplinary hospital. *Int. J. Risk. Saf. Med. Suppl* 1: S13-S14.
- Kilbre, H.S., Stevens, P.E., Eaglestone, G., Knight, S., Carter, J.L., Delaney, M.P., Farmer, C.K., Irving, J., O’Riordan, S.E., Dalton, R.N. & Lamb, E.J. 2013. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. *Am.J. Kidney Dis.* 61(1): 57-66.
- Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K. & Ray, S. 2007. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA.* 298(15): 1763-1771.
- Krol, G.D. 2011. Chronic Kidney Disease (CKD) Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers. Divisions of Nephrology & Hypertension and General Internal Medicine Henry Ford Health System.
- Lacy, C. F., 2013, *Drug Information Handbook 22nd edition*, American Pharmacists Association, Lexi-Comp.
- Le, J. Capparelli, E.V., Wahid, U., Shuan, Y., Romanowski, G.L., Tran, T.M., Nguyen, A. & Bradley, J.S. 2015. Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. *Clin. Ther.* 37(6): 1340-1351.
- Lepist, E.I. & Ray, A.S. Renal drug-drug interactions: what we have learned and where we are going. *Expert. Opin. Drug. Metab. Toxicol.* 8(4): 433-448.
- Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. & Roth, D. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann. Intern. Med.* 130(6): 461-470.
- Levey, A.S. & Coresh, J. 2002. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. *Am. J. Kidney. Dis.* 39: S1-S266
- Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Castro, A.F., Feldman, H.I., Kusek, J.W., Eggers, P., Van Lente, F., Greene, T. & Coresh, J. 2009. A New Equation to Estimate Glomerular Filtration Rate. *Ann. Intern. Med.* 150: 604-612.
- Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., Kaplan, S.L., Karchmer, A.W., Levine, D.P., Murray, B.E., Rybak, M.J., Talan, D.A. &

- Chambers, H.F. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin. Infect. Dis.* 52(3): 285-292.
- Lullman, H., Mohr, K., Ziegler, A., & Bieger, D. 2000. *Color Atlas of Pharmacology*. New York: Thieme.
- Matzke, G.R., McGory, R.W., Halstenson, C.E. and Keane, W.F. 1984. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrob. Agents Chemother.* 25: 433-437.
- Matzke, G.R., & Frye, R.F. 1997. Drug administration in patients with renal insufficiency: minimizing renal and external toxicity. *Drug Safety.* 16: 205-231.
- McEvoy, G.K. 2011. *AHFS Drug Information*. Bethesda, Maryland: American Society of Health-System Pharmacists®
- McKinnon, P.S. & Yu, V.L. 2004. Pharmacologic Considerations in Antimicrobial Therapy, with Emphasis on Pharmacokinetics and Pharmacodynamics: Reviews for the Practicing Clinician. *Eur. J. Clin. Microbiol. Infect. Dis.* 23: 231-232.
- Michels, W.M., Grootendorst, D.C., Verduijn, M., Elliot, E.G., Dekker, F.W. & Krediet, R.T. 2010. Performance of the Cockcroft-Gault, MDRD and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J. Am. Soc. Nephrol.* 5: 1003-1009.
- Moellering, R.C., Krogstad, D.J. & Greenblatt, D.J. 1981. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. *Ann. Intern. Med.* 94: 343-346.
- Myrna, Y., Munar & Harleen. 2007. Drug Dosing Adjustments in Patients with Chronic Kidney Disease. *Am. Fam. Physician.* 75(10): 1487-1496.
- Obach, R.S., Lombardo, F. & Waters, N.J. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in human for 670 drug compounds. *Drug Metab. Dispos.* 36(7): 1385-1405.
- Owens, R.C. & Shorr, A.F. 2009. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamics strategies. *Am. J. Health. Syst. Pharm.* 66: S23-30.
- Palylyk-Colwell, E., Jamali, F., Dryen, W., Friesen, E., Koven, S., Mohamed, I., Osmond, B., Alessi-Severini, S., Sheldon, L., Sheldon, R., Tam, Y., Tsuyuki, R., & Zhanel, G. 1998. Bioequivalence and interchangeability of narrow therapeutic range drugs. *J. Pharm. Pharm. Sci.* 1(1), 2-7.

- Pai, M.P., Neely, M., Rodvold, K.A. & Lodise, T.P. 2014. Innovative approaches to optimizing the delivery of vancomycin in individual patients. *Adv. Drug Deliv. Rev.* 77: 50-57.
- Panwar, B., Johnson, V.A., Patel, M. & Balkovetz, D.F. 2013. Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease. *Am J. Med. Sci.* 345: 396-399.
- Parfati, N., Budisutio, F. H. & Tan, C. K. 2004. Farmakokinetika Klinis dalam *Farmasi Klinis-Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien*, Editor Aslam, Moh, Chik Kaw Tan, Adji Prayitno. Jakarta: PT. Alex Media Komputindo.
- Patel, K., Crumby, A.S. & Maples, H.D. 2015. Balancing Vancomycin Efficacy and Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC. *Pediatr. Drugs.* 17(2): 97-103.
- Purwonugroho, T.A., Chulavatnatol, S., Preechagoon, Y., Chindavijak, B., Malathum, K., and Bunuparadah, P. Population Pharmacokinetics of Vancomycin in Thai Patients. *Sci. World J.* 2012: 1-8.
- Rice, P.J., Perry, R.J., Afzal, Z. & Stockley, I.H. 2003. Antibacterial prescribing and warfarin: a review. *Br. Dent. J.*, 194(8): 411-415.
- Riviere, J.E. 2011. *Comparative Pharmacokinetics: Principles, Techniques, and Applications*. Second Edition, John Wiley & Sons, Inc.
- Rowland, H. and Tozer, T.N. 1980. *Clinical Pharmacokinetics, Concept and Applications*. Philadelphia: Lea & Febiger.
- Rubinstein, E., Keynan, Y. 2014. Vancomycin revisited-60 years later. *Front Public Health.* 31(2):217.
- Rule, A.D., Bailey, K.R., Schwartz, G.L., Khosla, S., Lieske, J.C., Melton, L.J.3rd. 2009. For estimating creatinine clearance measuring muscle mass gives better result than those based on demographics. *Kidney Int.* 75(10):1071-1078.
- Rybak, M.J. 2006. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. *CID.* 42: S35-S39.
- ^aRybak, M., Lomaestro, B., Rotschafer, J.C., Moellering, Jr.R., Craig, W. & Billeter, M. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacist, the Infectious Diseases Society of America, and the Society of Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am. J. Health. Syst.Pharm.* 66: 82-98.
- ^bRybak, M., Lomaestro, B., Rotschafer, J.C., Moellering, Jr.R., Craig, W., Billeter, M., Dalovisio, J.R. & Levine, D.P. 2009. Vancomycin Therapeutic Guidelines: A

Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clin. Infect. Dis.* 49: 325-327.

- Salazar, D.E., & Corcoran, G.B. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. *Am. J. Med.* 84(6): 1053-1060.
- Schwartz, A., Brion, L.P., & Spitzer, A. 1987. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents, *Pediatr. Clin. North. Am.* 34 (3): 571-590.
- Smith, D.A., Jones, B.C and Walker, D.K. 1996. Design of Drugs Involving the Concepts and Theories of Drug Metabolism and Pharmacokinetics. *Med. Res. Rev.* 16(3): 243-266.
- Sennang, N., Sulina, Badji, A., Hardjoeno. 2005. Laju Filtrasi Glomerulus Pada Orang Dewasa Berdasarkan Tes Klirens Kreatinin Menggunakan Persamaan Cockcroft-Gault dan Modification of Diet in Renal Disease. *J. Med. Nus.* 24(2): 80-84.
- Shargel, L., Wu-Pong, S., & Yu, A.B. 2005. *Applied Biopharmaceutics and Pharmacokinetics*. 5th Ed. New York: The Mc Graw-Hill Companies.
- Siau, K. 2009. Hypokalaemia and cardiac arrest complicating vancomycin and furosemide therapy : a case report. *Cases J.* 2 : 8244.
- Sihombing, J.P., Hakim, L., Kusharwanti, W. 2011. Evaluasi Dosis Digoksin Pada Pasien Gagal Jantung dengan Disfungsi Ginjal di RSUP Dr. Sardjito, Yogyakarta. *Journal of Management and Pharmacy Practice (JMPP)*. 1(3).
- Siregar, C.J.P. & Endang, K. 2006. *Farmasi Klinik Teori dan Terapan*. Jakarta, EGC.
- Smith, K.M., Riche, D.M. & Henyan, N.N. 2010. *Clinical Drug Data*. New York: The Mc Graw-Hill Companies.
- Song, K.H., Kim, H.B., Kim, H.S., Lee, M.J., Jung, Y., Kim, G., Hwang, J.H., Kim, N.H., Kim, M., Kim, C.J., Choe, Pyoeng Gyun, Chung, J.Y., Park, W.B., Kim, E.S., Park, W.B., Kim, E.S., Park, K.U., Kim, N.J., Kim, E.C. & Oh, M.D. 2015. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant *Staphylococcus aureus* bacteraemia. *Int. J. Antimicrob. Agents.* 10(15): 331-333.
- Stengel, B. 2010. Chronic kidney disease and cancer: a troubling connection. *J. Nephrol.* 23(3): 253-263.
- Stepensky, D. 2013. Prediction of drug disposition on the basis of its chemical structure. *Clin. Pharmacokinet.* 52(6): 415-431.

- Sweetman, S.C. 2009. *Martindale : The Complete Drug Reference*, 36th Edition, Pharmaceutical Press London.
- Tandi, M., Mongan, A. & Manopo, F., 2014. Hubungan Antara Derajat Penyakit Ginjal Kronik Dengan Nilai Agregasi Trombosit di RSUP Prof. Dr. D. Kandou Manado. *J. eBM*. 2(2): 509-513.
- Taylor, M.E. & Allon, M. 2010. Practical Vancomycin Dosing in Hemodialysis Patients in the Era of Emerging Vancomycin Resistance: A Single-Center Experience. *Am. J. Kidney Dis*. 55(6): 1163-1165.
- Tiong, H.Y., Huang, P., Xiong, S., Li, Y., Vathsala, A. & Zink, D. 2014. Drug-Induced Nephrotoxicity: Clinical Impact and Preclinical *in Vitro* Models. *Mol. Pharmaceutics*. 11(7): 1933-1948.
- Traub, S.L., & Johnson, C.E. 1980. Comparison of method of estimating creatinine clearance in children. *Am.J. of Hosp. Pharm*. 37: 195-201.
- Trissel, 2011, *Handbook on Injectable Drugs*, 16th Edition. Bethesda, Maryland: American Society of Hospital Pharmacists, Inc.
- UK Health Departements. 2009. *British National Formulary 57*. London: BMJ Group & RPS Publishing.
- Urso, R., Bardi, P. & Giorgi, G. 2002. A short introduction to pharmacokinetics. *Eur. Rev. Med. Pharmacol. Sci*. 6: 33-44.
- Vacher, V.L., Izzedine, H., Mercadal, L. & Deray, G. 2002. Clinical review: Use of vancomycin in haemodialysis patients. *J. Crit. Care*. 6: 313-316.
- Valente, M.A., Hillege, H.L., Navis, G., Voors, A.A., Dunselman, P.H., van Veldhuisen, D.J. & Damman, K. 2014. The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. *Eur. J. Heart. Fail*. 16(1): 86-94.
- van Hal, S.J., Paterson, D.L. & Lodise, T.P. 2013. Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter. *Antimicrob. Agents and Chemother*. 57(2): 734-744.
- Vandecasteele, S.J & De Vriese, A.S. 2010. Recent changes in vancomycin use in renal failure. *Kidney Int*. 77: 760-764.
- Vandecasteele, S.J & De Vriese, A.S. 2011. Vancomycin Dosing in Patients on Intermittent Hemodialysis. *Seminar in Dialysis*. 24(1): 50-55.
- Vandecasteele, S.J., De Vriese, A.S. & Tacconelli, E. 2013. The Pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. *J. Antimicrob. Chemother*. 68: 743-748.

- Wagner, J. & Nelson, E. 1964. Wagner-Nelson Method. *J. Pharm. Sci.* 53: 1392.
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L. & DiPiro, C.V. 2015. *Pharmacotherapy Handbook*. New York: McGraw-Hill.
- Ye, Z.K., Tang, H.L. & Zhai, S.D. 2013. Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis. *PLoS.* 8(10): 1-10
- Yulianti, T., Hakim, L. & Putranto, W. 2007. *Evaluasi Penggunaan Antibiotik pada Pasien Penyakit Ginjal Kronik Rawat Inap di RSUP Dr. Moewardi Surakarta Periode September – November 2007* (Tesis). Yogyakarta: UGM
- Zorgani, A.A., Elahmer, O., Abaid, A., Elaref, A., Elamri, S., Aghila, E. & Tubbal, A. 2015. Vancomycin susceptibility trends of methicillin-resistant *Staphylococcus aureus* isolated from burn wounds: a time for action. *J. Infect. Dev. Ctries.* 9(11): 1284-1288.

